Prevention of hepatocellular carcinoma: Beyond hepatitis B vaccination

Seminars in Oncology

Volumn 42, Issue 2, 2015, Pages 316-328

  Kim, Mi Na ^a   Han, Kwang Hyub ^a,b   Ahn, Sang Hoon ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; INTERFERON; NUCLEOTIDE DERIVATIVE; VIRUS DNA; ANTIVIRUS AGENT; HEPATITIS VACCINE;

ADJUVANT THERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; DISEASE COURSE; DISEASE SURVEILLANCE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MASS IMMUNIZATION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; VACCINATION; VIRUS REPLICATION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; LIVER NEOPLASMS; MASS SCREENING; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MASS SCREENING; VIRAL HEPATITIS VACCINES;

EID: 84926304683     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.12.018     Document Type: Review

References (98)

1. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2 2005 74 108
2. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Estimating the world cancer burden: Globocan. 2000 Int J Cancer 94 2 2001 153 156
3. K.H. Han, and S.H. Ahn How to predict HCC development in patients with chronic B viral liver disease? Intervirology 48 1 2005 23 28
4. A.S. Lok, and B.J. McMahon Chronic hepatitis B Hepatology 45 2 2007 507 539
5. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2 2004 97 107
6. Y.J. Yoon, H.Y. Chang, and S.H. Ahn MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection Carcinogenesis 29 6 2008 1192 1196
7. Y.F. Liaw, D.Y. Lin, T.J. Chen, and C.M. Chu Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study Liver 9 4 1989 235 241
8. S.H. Ahn, Y.N. Park, and J.Y. Park Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance J Hepatol 42 2 2005 188 194
9. B.K. Kim, K.H. Han, and S.H. Ahn Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection Oncology 81 Suppl 1 2011 41 49
10. A.R. Zanetti, P. Van Damme, and D. Shouval The global impact of vaccination against hepatitis B: a historical overview Vaccine 26 49 2008 6266 6273
11. R.P. Beasley Rocks along the road to the control of HBV and HCC Ann Epidemiol 19 4 2009 231 234
12. Y.H. Ni, M.H. Chang, and L.M. Huang Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination Ann Intern Med 135 9 2001 796 800
13. M.H. Chang Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization Liver Int 23 5 2003 309 314
14. X. Liang, S. Bi, and W. Yang Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination Vaccine 27 47 2009 6550 6557
15. J. Gwack, S.K. Park, E.H. Lee, B. Park, Y. Choi, and K.Y. Yoo Hepatitis B vaccination and liver cancer mortality reduction in Korean children and adolescents Asian Pac J Cancer Prev 12 9 2011 2205 2208
16. R. Bhimma, H.M. Coovadia, M. Adhikari, and C.A. Connolly The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy Arch Pediatr Adolesc Med 157 10 2003 1025 1030
17. P. Bonanni, G. Pesavento, and A. Bechini Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy Vaccine 21 7-8 2003 685 691
18. A.R. Zanetti, A. Mariano, and L. Romano Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study Lancet 366 9494 2005 1379 1384
19. M. Piazza, G. Da Villa, and L. Picciotto Mass vaccination against hepatitis B in infants in Italy Lancet 2 8620 1988 1132
20. A.R. Zanetti, E. Tanzi, L. Romano, and I. Grappasonni Vaccination against hepatitis B: the Italian strategy Vaccine 11 5 1993 521 524
21. P. Bonanni, and P. Crovari Success stories in the implementation of universal hepatitis B vaccination: an update on Italy Vaccine 16 Suppl 1998 S38 42
22. G. Da Villa, L. Romano, and A. Sepe Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals Vaccine 25 16 2007 3133 3136
23. M.H. Chang, C.J. Chen, and M.S. Lai Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group N Engl J Med 336 26 1997 1855 1859
24. M.H. Chang, S.L. You, and C.J. Chen Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a. 20-year follow-up study J Natl Cancer Inst 101 19 2009 1348 1355
25. K. Wichajarn, P. Kosalaraksa, and S. Wiangnon Incidence of hepatocellular carcinoma in children in Khon Kaen before and after national hepatitis B vaccine program Asian Pac J Cancer Prev 9 3 2008 507 509
26. A.P. Lanier, P. Holck, G. Ehrsam Day, and C. Key Childhood cancer among Alaska Natives Pediatrics 112 5 2003 e396
27. H.F. Hung, and T.H. Chen Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence Vaccine 27 48 2009 6770 6776
28. A. Plymoth, S. Viviani, and P. Hainaut Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention Cancer Lett 286 1 2009 15 21
29. C.J. Chen, H.I. Yang, and J. Su Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 1 2006 65 73
30. C.F. Wu, M.W. Yu, and C.L. Lin Long-term tracking of hepatitis B viral load and the relationship with risk for hepatocellular carcinoma in men Carcinogenesis 29 1 2008 106 112
31. J.D. Chen, H.I. Yang, and U.H. Iloeje Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death Gastroenterology 138 5 2010 1747 1754
32. M.F. Yuen, C.K. Hui, C.C. Cheng, C.H. Wu, Y.P. Lai, and C.L. Lai Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications Hepatology 34 1 2001 139 145
33. K. Krogsgaard The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment J Viral Hepat 5 6 1998 389 397
34. G. Mazzella, G. Saracco, and D. Festi Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial Am J Gastroenterol 94 8 1999 2246 2250
35. P. Tangkijvanich, D. Thong-ngam, V. Mahachai, N. Kladchareon, P. Suwangool, and P. Kullavanijaya Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B Southeast Asian J Trop Med Public Health 32 3 2001 452 458
36. G.V. Papatheodoridis, E. Manesis, and S.J. Hadziyannis The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B J Hepatol 34 2 2001 306 313
37. B.X. Truong, Y. Seo, and M. Kato Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha Int J Mol Med 16 2 2005 279 284
38. S.M. Lin, I.S. Sheen, R.N. Chien, C.M. Chu, and Y.F. Liaw Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection Hepatology 29 3 1999 971 975
39. K. Ikeda, S. Saitoh, and Y. Suzuki Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study Cancer 82 5 1998 827 835
40. S.M. Lin, M.L. Yu, and C.M. Lee Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma J Hepatol 46 1 2007 45 52
41. S.M. Lin, D.I. Tai, R.N. Chien, I.S. Sheen, C.M. Chu, and Y.F. Liaw Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B J Viral Hepat 11 4 2004 349 357
42. C. Camma, M. Giunta, P. Andreone, and A. Craxi Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach J Hepatol 34 4 2001 593 602
43. J.J. Sung, K.K. Tsoi, V.W. Wong, K.C. Li, and H.L. Chan Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma Aliment Pharmacol Ther 28 9 2008 1067 1077
44. Y.F. Yang, W. Zhao, Y.D. Zhong, H.M. Xia, L. Shen, and N. Zhang Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis J Viral Hepat 16 4 2009 265 271
45. Y. Miyake, H. Kobashi, and K. Yamamoto Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection J Gastroenterol 44 5 2009 470 475
46. C.L. Lai, and M.F. Yuen Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy Hepatology 57 1 2013 399 408
47. J. Fung, C.L. Lai, W.K. Seto, and M.F. Yuen Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B J Antimicrob Chemother 66 12 2011 2715 2725
48. M.F. Yuen, W.K. Seto, and D.H. Chow Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease Antivir Ther 12 8 2007 1295 1303
49. Y.F. Liaw, J.J. Sung, and W.C. Chow Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 15 2004 1521 1531
50. J.R. Eun, H.J. Lee, T.N. Kim, and K.S. Lee Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease J Hepatol 53 1 2010 118 125
51. A. Matsumoto, E. Tanaka, and A. Rokuhara Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients Hepatol Res 32 3 2005 173 184
52. V. Di Marco, A. Marzano, and P. Lampertico Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine Hepatology 40 4 2004 883 891
53. M. Kurokawa, N. Hiramatsu, and T. Oze Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection J Gastroenterol 47 5 2012 577 585
54. P. Lampertico, M. Vigano, E. Manenti, M. Iavarone, E. Sablon, and M. Colombo Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients Gastroenterology 133 5 2007 1445 1451
55. G.V. Papatheodoridis, S. Manolakopoulos, and G. Touloumi Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study Gut 60 8 2011 1109 1116
56. C.H. Kim, S.H. Um, and Y.S. Seo Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents J Gastroenterol Hepatol 27 10 2012 1589 1595
57. T. Hosaka, F. Suzuki, and M. Kobayashi Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection Hepatology 58 1 2013 98 107
58. G.L. Wong, H.L. Chan, and C.W. Mak Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis Hepatology 58 5 2013 1537 1547
59. T.T. Chang, Y.F. Liaw, and S.S. Wu Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B Hepatology 52 3 2010 886 893
60. R. Zoutendijk, J.G. Reijnders, and F. Zoulim Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis Gut 62 5 2013 760 765
61. G.V. Papatheodoridis, P. Lampertico, S. Manolakopoulos, and A. Lok Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review J Hepatol 53 2 2010 348 356
62. J.Y. Cho, Y.H. Paik, and W. Sohn Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease Gut 63 12 2014 1943 1950
63. Y.H. Park, B.K. Kim, and J.K. Kim Long-term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea J Gastroenterol Hepatol 29 5 2014 1005 1011
64. S.G. Lim, R. Mohammed, M.F. Yuen, and J.H. Kao Prevention of hepatocellular carcinoma in hepatitis B virus infection J Gastroenterol Hepatol 24 8 2009 1352 1357
65. B.K. Kim, K.H. Han, and Y.N. Park Prediction of microvascular invasion before curative resection of hepatocellular carcinoma J Surg Oncol 97 3 2008 246 252
66. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 3 2011 1020 1022
67. F. Farinati, D. Marino, and M. De Giorgio Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101 3 2006 524 532
68. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements J Gastroenterol Hepatol 25 4 2010 657 663
69. K.H. Han, Y. Kim do, and J.Y. Park Survival of hepatocellular carcinoma patients may be improved in surveillance interval not more than 6 months compared with more than 6 months: a 15-year prospective study J Clin Gastroenterol 47 6 2013 538 544
70. D.Y. Lin, S.M. Lin, and Y.F. Liaw Non-surgical treatment of hepatocellular carcinoma J Gastroenterol Hepatol 12 9-10 1997 S319 S328
71. M.W. Yu, H.C. Chang, and Y.F. Liaw Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives J Natl Cancer Inst 92 14 2000 1159 1164
72. B.H. Zhang, B.H. Yang, and Z.Y. Tang Randomized controlled trial of screening for hepatocellular carcinoma J Cancer Res Clin Oncol 130 7 2004 417 422
73. T.S. Mok, W. Yeo, and S. Yu An intensive surveillance program detected a high incidence of hepatocellular carcinoma among hepatitis B virus carriers with abnormal alpha-fetoprotein levels or abdominal ultrasonography results J Clin Oncol 23 31 2005 8041 8047
74. Y. Kim do, Y.H. Paik, and S.H. Ahn PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection Oncology 72 Suppl 1 2007 52 57
75. Y.J. Yoon, K.H. Han, and Y. Kim do Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection Scand J Gastroenterol 44 7 2009 861 866
76. L. Bolondi Screening for hepatocellular carcinoma in cirrhosis J Hepatol 39 6 2003 1076 1084
77. A. Sangiovanni, E. Del Ninno, and P. Fasani Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance Gastroenterology 126 4 2004 1005 1014
78. J.M. Llovet, A. Burroughs, and J. Bruix Hepatocellular carcinoma Lancet 362 9399 2003 1907 1917
79. H. Imamura, Y. Matsuyama, and E. Tanaka Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy J Hepatol 38 2 2003 200 207
80. J.M. Llovet, and J. Bruix Novel advancements in the management of hepatocellular carcinoma in. 2008 J Hepatol 48 Suppl 1 2008 S20 S37
81. J.C. Wu, Y.H. Huang, and G.Y. Chau Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma J Hepatol 51 5 2009 890 897
82. B.K. Kim, J.Y. Park, and Y. Kim do Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection Liver Int 28 3 2008 393 401
83. S.M. Lin, C.J. Lin, and C.W. Hsu Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors Cancer 100 2 2004 376 382
84. C.M. Lo, C.L. Liu, and S.C. Chan A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma Ann Surg 245 6 2007 831 842
85. H.C. Sun, Z.Y. Tang, and L. Wang Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial J Cancer Res Clin Oncol 132 7 2006 458 465
86. V. Mazzaferro, R. Romito, and M. Schiavo Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis Hepatology 44 6 2006 1543 1554
87. K. Ikeda, Y. Arase, and S. Saitoh Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer Hepatology 32 2 2000 228 232
88. Y. Shiratori, S. Shiina, and T. Teratani Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus Ann Intern Med 138 4 2003 299 306
89. S. Kubo, S. Nishiguchi, K. Hirohashi, H. Tanaka, T. Shuto, and H. Kinoshita Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy Br J Surg 89 4 2002 418 422
90. S. Kubo, S. Nishiguchi, and K. Hirohashi Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial Ann Intern Med 134 10 2001 963 967
91. S. Breitenstein, D. Dimitroulis, H. Petrowsky, M.A. Puhan, B. Mullhaupt, and P.A. Clavien Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis Br J Surg 96 9 2009 975 981
92. Y.C. Shen, C. Hsu, L.T. Chen, C.C. Cheng, F.C. Hu, and A.L. Cheng Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach J Hepatol 52 6 2010 889 894
93. L.S. Qu, F. Jin, X.W. Huang, and X.Z. Shen Interferon-alpha therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma J Surg Oncol 102 7 2010 796 801
94. L. Wang, W.Z. Wu, and H.C. Sun Mechanism of interferon alpha on inhibition of metastasis and angiogenesis of hepatocellular carcinoma after curative resection in nude mice J Gastrointest Surg 7 5 2003 587 594
95. S. Kubo, H. Tanaka, and S. Takemura Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus Hepatol Res 37 2 2007 94 100
96. Y. Urata, S. Kubo, and S. Takemura Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma J Hepatobiliary Pancreat Sci 19 6 2012 685 696
97. C.Y. Wu, Y.J. Chen, and H.J. Ho Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection JAMA 308 18 2012 1906 1914
98. Y. Zhou, Z. Zhang, Y. Zhao, L. Wu, and B. Li Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis World J Surg 38 9 2014 2395 2402